← FDA DRUG APPROVALS

FDA ANDA · ANDA088563

THIORIDAZINE HYDROCHLORIDE

Sponsor: WATSON LABS

APPLICATION
ANDA088563
TYPE
ANDA
ORIGINAL APPROVAL
1984-05-11
LATEST ACTION
2017-02-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

THIORIDAZINE HYDROCHLORIDEDiscontinued
THIORIDAZINE HYDROCHLORIDE 50MG · TABLET · ORAL

Approval history

2017-02-24Labeling · Supplement 29 · standardAP
2015-11-03Labeling · Supplement 28AP
1997-01-31Manufacturing (CMC) · Supplement 27AP
1991-02-04Labeling · Supplement 26AP
1990-09-17Labeling · Supplement 25AP
1988-09-27Manufacturing (CMC) · Supplement 23AP
1988-09-27Manufacturing (CMC) · Supplement 24AP
1988-09-27Manufacturing (CMC) · Supplement 22AP
1988-07-05Labeling · Supplement 21AP
1987-10-26Manufacturing (CMC) · Supplement 18AP
1987-05-15Manufacturing (CMC) · Supplement 17AP
1986-02-05Manufacturing (CMC) · Supplement 14AP
1985-11-25Manufacturing (CMC) · Supplement 11AP
1985-11-25Manufacturing (CMC) · Supplement 12AP
1985-11-25Manufacturing (CMC) · Supplement 9AP
1985-01-11Manufacturing (CMC) · Supplement 4AP
1985-01-11Manufacturing (CMC) · Supplement 2AP
1984-05-11OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →